---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-310169"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-12-21T23:59:59+00:00"
generated_at: "2026-06-21T00:59:15.455287+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M

## Summary
- Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.
- ORIC and Pfizer will conduct a Phase 2 study of ORIC-533 combined with elranatamab in multiple myeloma.
- Jeff Settleman, Pfizer Oncology CSO, joins ORIC's Scientific Advisory Board.
- ORIC retains full ownership of ORIC-533; net proceeds extend cash runway into 1H 2025.
- Offering expected to close Dec 23, 2022; no underwriter or placement agent involved.

## SEC filing metadata
- accession: 0001193125-22-310169
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/0001193125-22-310169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/d399008d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-310169
- JSON: https://secwatch.observer/filing/0001193125-22-310169.json
- Plain text: https://secwatch.observer/filing/0001193125-22-310169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.